LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Da

Event · Earnings
Original reporting
Published Nov 16, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LONA
Bullish
medium confidence
Mentioned
$LONA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LONABullishMed
01

Why it matters

This 8-K provides a primary update on financial condition (cash, burn, expense run-rate) and a near-term operational milestone for ELAINE-3 enrollment, which is a key determinant of the next valuation inflection toward 2H 2027 topline data.

02

Market read

Traders can reassess near-term biotech risk around ELAINE-3 enrollment completion and financing runway based on the updated cash and burn figures.

03

What to watch

Cash fell to $32.3M from $88.3M year-end, and R&D and operating cash burn increased sharply, which can raise financing overhang even if enrollment progresses.

Relevance 7/10Novelty 7/10Timing: after-hours filing on 2026-11-16, with investors reacting to updated cash burn and ELAINE-3 enrollment timeline

Background

LeonaBio is a clinical-stage biopharma focused on lasofoxifene (Phase 3 ELAINE-3) for ER+, HER2-negative, ESR1-mutated metastatic breast cancer, plus brelgometon (ATH-1105) in early ALS development.

Company-level read

Ticker impact

$LONABullishMedium confidence
Context

LeonaBio reports Q3 2026 results and says enrollment for Phase 3 ELAINE-3 is nearing completion in 4Q 2026, with topline data expected in 2H 2027.

Expected impact

Likely modest upward bias as investors price reduced enrollment risk and improved visibility into the next major catalyst.

Evidence & confidence

The article is a primary SEC 8-K with cash and operating expense figures plus a concrete clinical timeline update, but it does not provide new efficacy data or guidance beyond the stated enrollment and topline expectations.

Market effects

Adds incremental sentiment support for ER+/ESR1-mutated metastatic breast cancer SERM programs and CDK4/6 combination strategies, but without new Phase 3 efficacy data.

No clear regional market linkage beyond US small-cap biotech sentiment.

Limited global read-through since the catalyst is company-specific clinical execution and US-listed issuer reporting.

Counterpoint

Enrollment “nearing completion” can still slip; without updated enrollment numbers or site activation metrics, the market may over-discount timeline risk.

Key entities

  • LeonaBio, Inc.

    NASDAQ-listed clinical-stage biopharmaceutical company reporting Q3 2026 results and ELAINE-3 enrollment progress.

  • Lasofoxifene

    Third-generation nonsteroidal SERM in Phase 3 ELAINE-3 with abemaciclib for ESR1-mutated metastatic breast cancer.

  • ELAINE-3

    Phase 3 trial targeting enrollment completion in 4Q 2026, with topline data expected in 2H 2027.

  • Brelgometon (ATH-1105)

    Brain-penetrant small molecule in Phase 1/expected Phase 2 proof-of-concept for ALS.

Related articles

$LONAMed

In December 2025, as part of a private placement, LeonaBio, Inc. issued warrants to purchase an aggregate of 23,031,494 shares of its common stock

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. In December 2025, as part of a private placement, LeonaBio, Inc. (the “Company”) issued warrants to purchase an aggregate of 23,031,494 shares of its common stock (the “Series A Common Warrants”). The Series A Common Warrants have an exercise price of $6.3

$LONAMed

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

LeonaBio (NASDAQ:LONA) reported a Q2 loss of $0.80 per share, smaller than analysts’ $1.12 forecast. Net loss rose to $19.0 million from $7.0 million a year earlier. Phase 3 ELAINE-3 enrollment nears 600 target, with 495 patients enrolled and topline results expected in H2 2027. Cash fell to $51.1 million from $88.3 million.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.

$GLADMed

Gladstone Capital (GLAD) Q4 2026 Earnings Call Transcript

Gladstone Capital (GLAD) reported Q4 2026 earnings with net interest margin at 8.2%. Fee income was below average, but incentive fee credit covered 100% of regular distributions. Net asset value declined to $20.77 per share due to unrealized depreciation and a supplemental distribution. Total investment income rose 11.7% for the year, covering distributions at 104.5%. The company discussed its investment strategy and credit management, highlighting its focus on the lower middle market.